FDA Sets Final Rules for Prescription Drug Companion and Standalone Apps
Start here
On October 20, 2026, the FDA issued final guidance establishing a framework for developing, distributing, and labeling apps and software that accompany prescription drugs. The guidance draws a key distinction: companion apps connected to a medical device, such as an app paired with an inhaler, generally must be described on the drug's prescribing label. Standalone apps, including symptom trackers, dose reminders, and health coaching tools, appear on the label only if demonstrated to be essential for safe and effective use or to provide a significant clinical benefit. Developers and drug makers now have a settled standard for labeling decisions, though how the agency applies the essential-use and clinical-benefit thresholds to individual products will be worked out case by case.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- U.S. FDAPickFDA Issues Final Guidance on Prescription Drug Apps and Software
On October 20, 2026, the FDA issued final guidance establishing a framework for developing, distributing, and labeling apps and software that accompany prescription drugs. The guidance distinguishes between companion apps connected to a medical device (such as an inhaler companion app), which generally must be described on the drug's prescribing label, and standalone apps (symptom trackers, dose reminders, health coaching tools), which belong on the label only if shown to be essential for safe and effective use or to provide a significant clinical benefit.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 20 22:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.